Key facts
- It has raised $1.6M; the latest was Early Stage VC in Feb 2026.
- Notable investors include Xinghua Dingli Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Norroy Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Norroy Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Norroy Bioscience
Developer of precision medicine intended to treat cancers. The company develops nuclear medicines, committing to treating pancreatic cancer, kidney cancer, stomach cancer, ovarian cancer, prostate cancer, and Parkinson's disease through precision medicine, providing treatment for cancers.
- Sector
- Healthcare
- HQ
- Wuxi, China
- Founded
- 2021
- Website
- norroybioscience.com/
- Ownership
- Privately Held (backing)
Norroy Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Norroy Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Norroy Bioscience in its N-PORT filings yet. We sweep new filings monthly.